We are live on ! Find out more
DNTH icon

Dianthus Therapeutics
DNTH

90 hedge funds and large institutions have $418M invested in Dianthus Therapeutics in 2021 Q1 according to their latest regulatory filings, with 12 funds opening new positions, 26 increasing their positions, 29 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

306% more call options, than puts

Call options by funds: $739K | Put options by funds: $182K

64% more capital invested

Capital invested by funds: $255M → $418M (+$163M)

0.34% more ownership

Funds ownership: 4.21% → 4.55% (+0.34%)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

2% less funds holding

Funds holding: 92 → 90 (-2)

10% less repeat investments, than reductions

Existing positions increased: 26 | Existing positions reduced: 29

14% less first-time investments, than exits

New positions opened: 12 | Existing positions closed: 14

Holders
90
Holders Change
-2
Holders Change %
-2.17%
% of All Funds
1.58%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.04%
New
12
Increased
26
Reduced
29
Closed
14
Calls
$739K
Puts
$182K
Net Calls
+$557K
Net Calls Change
+$675K

Top Buyers

1
O
OrbiMed
New York
+$9.98M
2
Citadel Advisors
Citadel Advisors
Florida
+$7.1M
3
CAM
Cormorant Asset Management
Massachusetts
+$6.31M
4
Fidelity Investments
Fidelity Investments
Massachusetts
+$6.05M
5
EC
EcoR1 Capital
California
+$5.85M

Top Sellers

1
EAM
Eventide Asset Management
Massachusetts
-$7.84M
2
Morgan Stanley
Morgan Stanley
New York
-$3.85M
3
Renaissance Technologies
Renaissance Technologies
New York
-$1.68M
4
TCM
Tekla Capital Management
Massachusetts
-$1.51M
5
PM
Prosight Management
Texas
-$985K
Name Holding Trade Value Shares
Change 		Change in
Stake
Dimensional Fund Advisors
26
Dimensional Fund Advisors
Texas
$2.25M +$1M +5,943 +100%
ACM
27
Altium Capital Management
New York
$1.95M +$1.73M +10,274 New
Two Sigma Investments
28
Two Sigma Investments
New York
$1.87M -$423K -2,512 -20%
Jacobs Levy Equity Management
29
Jacobs Levy Equity Management
New Jersey
$1.78M -$473K -2,809 -23%
N
30
Nuveen
North Carolina
$1.62M -$70K -416 -5%
Truist Financial
31
Truist Financial
North Carolina
$1.31M -$226K -1,344 -16%
Bank of America
32
Bank of America
North Carolina
$1.29M +$967K +5,744 +550%
Federated Hermes
33
Federated Hermes
Pennsylvania
$1.2M +$1.02M +6,038 +2,061%
SCM
34
Soleus Capital Management
Connecticut
$1.18M +$1.05M +6,250 New
OM
35
Opaleye Management
Massachusetts
$1.05M +$427K +2,537 +85%
AA
36
ALPS Advisors
Colorado
$1.04M +$6.56K +39 +0.7%
FAM
37
Fred Alger Management
New York
$941K +$836K +4,969 New
Bank of New York Mellon
38
Bank of New York Mellon
New York
$788K -$13K -77 -2%
IHAM
39
Integral Health Asset Management
New York
$770K +$684K +4,063 New
Goldman Sachs
40
Goldman Sachs
New York
$730K -$168K -998 -21%
Charles Schwab
41
Charles Schwab
California
$648K +$40.2K +239 +8%
SFI
42
Susquehanna Fundamental Investments
Pennsylvania
$604K -$44.1K -262 -8%
Millennium Management
43
Millennium Management
New York
$513K -$229K -1,363 -33%
CS
44
Credit Suisse
Switzerland
$510K -$157K -932 -26%
AG
45
Algert Global
California
$507K +$58.9K +350 +15%
Barclays
46
Barclays
United Kingdom
$415K -$37.7K -224 -9%
Russell Investments Group
47
Russell Investments Group
United Kingdom
$414K -$458K -2,720 -55%
AllianceBernstein
48
AllianceBernstein
Tennessee
$406K -$48.3K -287 -12%
California Public Employees Retirement System
49
California Public Employees Retirement System
California
$395K -$40.4K -240 -10%
California State Teachers Retirement System (CalSTRS)
50
California State Teachers Retirement System (CalSTRS)
California
$371K – – –
1
2
3 4 5

DNTH Hedge Fund Activity: Q1 2021 in Review

90 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Dianthus Therapeutics (DNTH) for Q1 2021, worth a combined $418M — up 64% from $255M a quarter earlier.

Sellers outnumbered buyers: 14 funds closed out of DNTH and 12 opened new positions — a net loss of 2 holders — while 29 trimmed existing stakes and 26 added.

The largest buyer was OrbiMed, opening a new position worth an estimated $9.98M. The largest seller was Eventide Asset Management, exiting entirely with an estimated $7.84M sold.

  • 90 institutional investors held Dianthus Therapeutics (DNTH) as of Q1 2021, down from 92 in Q4 2020.
  • Funds reported $418M of Dianthus Therapeutics stock for Q1 2021, up 64% quarter-over-quarter.
  • 12 funds opened new Dianthus Therapeutics positions in Q1 2021 and 14 closed out, a net change of -2 holders.
  • The largest Dianthus Therapeutics buyer in Q1 2021 was OrbiMed, an estimated $9.98M added.
  • The largest Dianthus Therapeutics seller in Q1 2021 was Eventide Asset Management, an estimated $7.84M sold.

Based on aggregated 13F filings for Q1 2021.